Dr Reddy’s Laboratories is expanding its push into the fast-growing market for GLP-1 medicines, with chief executive Erez Israeli saying the company has already applied for approval in more than 80 countries, including the United States. The move reflects rising global demand for lower-cost diabetes and weight-management treatments as pharmaceutical companies race to bring generic alternatives to market.
Israeli said Dr Reddy’s expects its generic GLP-1 product to become available soon in several regions outside the West, including South America, Africa and most of Asia. Canada is also among the markets where the company expects access to the medicine. However, the product is not expected to be available in the US, the UK or Europe in the near term.
The company’s strategy appears focused on markets where regulatory pathways and commercial opportunities may be more favorable for a generic version. GLP-1 drugs have become some of the most sought-after medicines in the world because of their strong effects in treating type 2 diabetes and supporting weight loss. As demand has surged, interest has grown in making these medicines more widely available at lower prices.
By applying in more than 80 countries, Dr Reddy’s is signaling an ambitious global rollout plan. The company is positioning itself to compete in a market that has attracted intense attention from both branded drugmakers and generics manufacturers. For many countries, access to cheaper versions of GLP-1 therapies could significantly expand treatment options for patients and healthcare systems facing high costs.
Israeli’s comments suggest the company is targeting a broad international footprint while avoiding some of the most tightly controlled and competitive pharmaceutical markets. The absence of expected availability in the US, UK and Europe indicates that approval and commercialization in those regions may face additional hurdles, whether regulatory, legal or market-related.
The announcement also highlights the growing importance of generic drugmakers in making advanced treatments more accessible worldwide. As GLP-1 therapies continue to dominate the conversation around diabetes and obesity care, companies like Dr Reddy’s are looking to capture demand in emerging and developing markets where affordability remains a major barrier.
For patients and health providers in many parts of the world, the arrival of a generic GLP-1 option could offer a more affordable alternative to branded medicines that have until now been out of reach for many. Dr Reddy’s expects that rollout to gather pace across multiple regions, adding another contender to the global race for access to one of the most in-demand drug classes in modern medicine.
The company’s expansion plan underscores how pharmaceutical competition is shifting beyond traditional Western markets. While the US and Europe remain major centers for drug development and sales, the broader international market is becoming increasingly important for companies seeking scale, revenue growth and wider public health impact.
